Schwarz Pharma Announces the Positive Results of Phase II Trial for Rotigotine CDS in Restless Legs Syndrome
Positive Phase II study shows dose-related reduction of symptoms. Results to be presented at 7th International Congress of Parkinson’s Disease and Movement Disorders in Miami, November 10-14, 2002.
Hopkinton, MA - Oct 10, 2002 - Aderis Pharmaceutical’s partner, Schwarz Pharma, announced the completion of a Phase II trial for Rotigiotine CDS in Restless Legs Syndrome. The study demonstrated evidence of clinically significant and dose-related improvement of symptoms. The results also showed clear improvements in daily life activities. A more comprehensive Phase II program will begin in the spring of 2003. Read the complete News release from Schwarz Pharma.
"At Aderis, we are excited about the progress of our product candidates and their potential ability to improve quality of life for millions of people. We are committed to helping patients and investors understand our progress as we achieve corporate and clinical milestones."
-Kenneth L. Rice, Jr.,
Chief Commercial Officer, Aderis Pharmaceuticals
back to top
